Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide.

MLA

Palella, Frank J., et al. “Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide.” JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 92, no. 1, Jan. 2023, pp. 67–75. EBSCOhost, https://doi.org/10.1097/QAI.0000000000003101.

APA

Palella, F. J., Hou, Q., Li, J., Mahnken, J., Carlson, K. J., Durham, M., Ward, D., Fuhrer, J., Tedaldi, E., Novak, R., & Buchacz, K. (2023). Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 92(1), 67–75. https://doi.org/10.1097/QAI.0000000000003101

Chicago

Palella, Frank J., Qingjiang Hou, Jun Li, Jonathan Mahnken, Kimberly J. Carlson, Marcus Durham, Douglas Ward, et al. 2023. “Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide.” JAIDS: Journal of Acquired Immune Deficiency Syndromes 92 (1): 67–75. doi:10.1097/QAI.0000000000003101.